ALM-401 / Almac Discovery, Formosa Labs - LARVOL DELTA

Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors (PRNewswire) - "Taiwan-based Formosa Pharmaceuticals...announced that the company has entered into an exclusive licensing agreement with Almac Discovery, a Northern Ireland-based research driven drug discovery company, for exclusive rights to the commercialization of ALM-401, a first-in-class, bispecific antibody drug conjugate (ADC) for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1...The licensing agreement includes upfront payment and development milestones, with additional considerations through approval and post-commercialization."

Licensing / partnership • Non Small Cell Lung Cancer • Solid Tumor

ALM-401: A first-in-class next generation bispecific ADC configured to deliver superior efficacy in selected solid tumor indications (AACR 2025) - "This bsADC significantly outperforms a zilovertamab vedotin biosimilar, which exhibits an ORR of 22% (2/9) in these models at the same payload equivalent dose. ALM-401 has excellent plasma stability, a PK profile in line with approved ADCs, and good overall manufacturing and developability characteristics, with the potential to deliver significantly improved patient outcomes across a range of solid tumor indications with high unmet need."

Clinical • Late-breaking abstract • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • ROR1